A bill to prohibit pharmacy benefit managers, insurers, and prescription drug or medical device wholesalers from being under common ownership with certain medical service providers, and for other purposes.

Legislative bill overview

S 3822 would prohibit pharmacy benefit managers (PBMs), insurers, and prescription drug/medical device wholesalers from being commonly owned with medical service providers like hospitals and physician practices. The bill aims to prevent vertical integration in the healthcare and pharmaceutical supply chain that could create conflicts of interest.

Why is this important

Vertical integration in healthcare can create incentive misalignments where companies profit from limiting competitor access to drugs or steering patients toward affiliated providers. This has real consequences for drug pricing, patient choice, and competition—affecting insurance premiums, out-of-pocket costs, and drug availability for consumers.

Potential points of contention

• Business model disruption: Companies like UnitedHealth Group, CVS Health, and others would face major restructuring, potentially requiring divestitures of significant business segments worth billions of dollars
• Implementation challenges: Defining "common ownership" thresholds, determining effective dates, and addressing existing integrated structures raises complex compliance questions
• Counterargument on efficiency: Proponents of integration argue consolidated ownership can reduce administrative costs and improve care coordination, potentially lowering some healthcare expenses
• Enforcement mechanisms: The bill's enforcement approach and whether existing arrangements would be grandfathered in remains unclear from the summary